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found no significant difference in OS between the group of 
patients with S100B levels >0.1 μg/L at baseline compared 
to those with < 0.1 μg/L. In the patients with recurrent glioma 
we found a significantly shorter OS for patients with raised 
levels. In both groups, S100B values did not change signifi-
cantly throughout the course of the disease. Serum S100B 
levels do not seem to have prognostic value in newly diag-
nosed glioma patients. In recurrent glioma patients S100B 
might be of value in terms of prognostication of survival.
Keywords Glioma · S100B · Survival · 
Chemotherapy · Prognosis
Introduction
Gliomas are the most common primary brain tumors in 
adults with a histological grade that ranges from low (WHO 
I, II) to high grade (WHO III, IV) [1]. Despite different treat-
ment regimens, such as radio- and chemotherapy, which 
have evolved over the past decade, survival is still limited. 
Various prognostic factors have been identified, such as age, 
histology, extent of resection, corticosteroid use, and Kar-
nofsky Performance Status (KPS) [2–7]. Currently the role 
of the genetic profile of gliomas is extensively being investi-
gated and seems to be a strong prognostic factor in survival 
and treatment response in glioma patients [8–10]. However, 
an easy to use serum biomarker to predict the prognosis in 
glioma patients would still be an asset for patient care. Serum 
levels of th  S100B protein may be valuable in this respect.
The S100B protein is one of the most studied markers of 
central nervous system (CNS) pathology. This cytoplasmic 
Ca2+-binding protein is highly expressed in the CNS where 
it s prima ily secreted by astrocytes and other glial cell 
types such as Schwann cells and oligodendrocytes [11–13]. 
Abstract The S100B protein is associated with brain dam-
age and a breached blood–br in barrier. A previous pilot 
study showed that high serum levels of S100B a e associ-
ated with shorter survival in gl om  pa ients. The aim of our 
study was to assess the prognostic value in terms of survival 
and longitudinal dynamics of serum S100B for pa i nts with 
newly diagnosed and recurrent glioma. We obtained blood 
samples from patients with newly d agnosed and recurrent 
glioma before the start (baseline) and at fixed time-points 
during temozolomide chemotherapy. S100B-data were 
dichotomized according to the upper limit of the reference 
value of 0.1 μg/L. Overall survival (OS) was estimated with 
Kaplan–Meier curves and groups were compared with the 
log rank analysis. To correct for potential confounders a 
Cox regression analysis was used. We included 86 patients 
with newly-diagnosed and 27 patients with recurrent glioma. 
Most patients in both groups had baseline serum levels 
within normal limits. In the newly diagnosed patients we 
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status, and were scheduled for postoperative treatment with 
concurrent radiotherapy (60 Gy in 30 fractions of 2 Gy) 
and chemotherapy (temozolomide 75 mg/m², 5 days/week 
for 6 weeks during radiotherapy) followed by six adjuvant 
courses of chemotherapy in the form of oral temozolo-
mide 150–200 mg/m² in cycles of 5 days in 4 weeks [37]. 
Serum samples were obtained at baseline (before the con-
comitant phase), before the adjuvant phase, and every three 
cycles thereafter until progressive disease or chemother-
apy-induced toxicity was apparent. From patients that had 
completed six adjuvant courses without radiological and/or 
clinical progression, serum samples were also acquired at 3 
and 7 months after treatment.
Recurrent glioma
For this group, patients were included who were diagnosed 
with radiologically and/or surgically confirmed tumor recur-
rence of a previously histologically confirmed glioma, and 
who were scheduled for treatment with chemotherapy.
Chemotherapy consisted of oral temozolomide in two 
possible regimens: a short cycle of 5 consecutive days in 
4 weeks in doses of 150–200 mg/m², or a long cycle of 21 
consecutive days in 4 weeks (‘3 weeks on, 1 week off’) in 
doses of 75 mg/m².
If patients previously had been treated with temozolo-
mide, they received PCV: a combination chemotherapy of 
110 mg/m² oral lomustine (CCNU) on day 1, followed by 
1.4 mg/m² intravenous vincristine on day 8, and 60 mg/m² of 
oral procarbazine from day 8 until 23 with repeated admin-
istration of 1.4 mg/m² intravenous vincristine on day 29. 
Cycles were repeated until clinical and/or radiological pro-
gression or chemotherapy-induced toxicity was apparent.
Serum samples in this group were obtained at baseline 
(before start of first cycle) and every three cycles thereafter 
during chemotherapy treatment.
Chemical analysis
All patients were seen in a single clinic. Blood was collected 
at the physician’s office by venous puncture and transported 
immediately to the adjacent clinical chemistry laboratory 
where it was centrifuged, aliquoted, frozen and stored at 
−20 °C until assay. The entire procedure was completed 
within 2 h from phlebotomy.
Serum S100B was measured by the commercially avail-
able immunologic assay Elecsys S100 (Roche/Cobas®) with 
a detection limit of < 0.005 μg/L. Intra-assay variation at 
0.06 and 0.31 µg/L was 1.9 and 1.0 % respectively (n =  10). 
Inter-assay variation at 0.197 and 2.46 µg/L was 1.6 and 
5.6 % respectively (n =  16; three lots of controls). All sam-
ples were analyzed without knowledge of the clinical status 
of the patient. Data were dichotomized with a cut off value 
This protein is also widely distributed in tissues outside the 
nervous system, such as melanocytes, chondrocytes, skel-
etal muscle cells and adipose tissue [14–17].
Astrocytes leak and actively secrete S100B into the 
extracellular environment during metabolic st ess, leading 
to raised levels in the cerebrospinal fluid (CSF) [18]. When 
the blood–brain barrier (BBB) is breach d, th  protein is 
subsequently released into the serum. S rum S100B is a
suggested marker for BBB integrity, because levels are also 
raised after chemically opening the BBB in the absence of 
cerebral damage [19].
In clinical practice raised serum levels of S100B have 
been found in numerous neurological disorders, such as 
traumatic brain injury and acute stroke. In these conditions 
raised serum S100B levels are positive y correlated with 
unfavourable neurological outcome, mortality and imaging 
characteristics [20–29]. Furthermore, serum S100B has an 
established role in the management of melanoma, especially 
in the prediction of respons  to system c therapy [30–33]. 
Raised serum levels of the pr tein have a potential role in 
the prediction and detection of brain metastasis in lung can-
cer patients as well [34].
In glioma patients little is known about the prognostic 
value of serum S100B and its l git d nal behaviour during
the course of the disease. Raised serum levels have been 
documented in glioblastoma patients [35]. Furthermore, a 
former pilot study showed a correlation between high serum 
S100B concentrations and a shorter surviva  in a small pop-
ulation of glioma patients [36]. Based on these results, we 
hypothesize that serum S100B c n be helpful in predicting 
prognosis in glioma patients.
The aim of this study was to prosp ctively evaluate the 
prognostic value and the longitudinal dynamics in terms 
of overall survival (OS) of serum S100B in patients with 
newly diagnosed and recurrent glioma uring treatment 
with chemotherapy.
Patients and methods
Between September 2004 and January 2013 patients wi h 
histological proven, newly diagnos d or recurrent glioma 
who were scheduled for chemoth rapy treatment and who 
visited the Neurology out-patient c inic of our institution, 
were included into a prospec ive study on the evaluation 
of side effects of chemotherapy. Informed consent was 
obtained by the treating physic an and the protocol of this
study was approved by the local Ethics Commi tee.
Newly diagnosed glioma
Patients in this group were eligibl if they were diagnosed 
with histologically proven glioma, had a good performance 
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The median survival after baseline blood sampling was 
12 months (1–74) with 4 out of 27 patients censored.
Serum S100B measurements
In the newly diagnosed group a median number of three 
serum samples (range 1–6) was obtained per patient. The 
median baseline serum S100B value was 0.049 µg/L (range 
0.015–0.459). Seven patients (8 %) had levels above the 
upper limit of the reference range of 0.1 µg/L, all diagnosed 
with glioblastoma multiforme with two patients demonstrat-
ing remarkably high serum levels of 0.313 and 0.459 µg/L. 
Median serum levels did not change significantly during 
follow-up (Fig. 1a). Age did not seem to interfere with 
S100B values as well (p =  0.557, independent t test).
The median number of serum samples obtained in the 
recurrent group was 2 (range 1–7) and the median baseline 
S100B value was 0.064 µg/L (0.020–0.430). Seven patients 
(26 %) had levels exceeding the reference value, of which 
six had been diagnosed with glioblastoma multiforme and 
one patient with oligodendroglioma WHO III. There was 
one patient with a high serum level of 0.430 µg/L, who had 
been diagnosed with glioblastoma multiforme. As in the 
newly diagnosed group no significant changes were found 
in median serum S100b levels during treatment with che-
motherapy (Fig. 1b). There was no significant difference 
in age between these two groups (p =  0.831, independent t 
test).
of 0.1 µg/L, which is considered to be the estimated upper 
limit of the reference range in serum [38–40].
Definition of outcome variables
Patients’ clinical records were reviewed to obtain infor-
mation concerning clinical and survival data. OS was 
defined as the interval between the date of baseline blood 
sampling and date of death. Tumor progression was 
defined according to the RANO criteria [41]. Age, tumor 
grade, baseline KPS and corticosteroid use were included 
as co-variables.
Statistical analysis
Kaplan–Meier curves were used to estimate OS times. To 
calculate significance between survival curves a log-rank 
test was used. A Cox proportional hazard analysis was used 
to assess the prognostic value of serum S100B, corrected 
for potential confounders. To calculate a significant change 
of S100B value during follow up a Mann–Whitney U test 
was used. A p-value of < 0.05 was used to determine sig-




Tables 1 and 2 list the patient charact ristics for th  newly 
diagnosed and recurrent glioma patient groups respectively.
Ninety-seven patients were newly diagnos d with gli-
oma, had undergone cranial surgery and were scheduled 
for postoperative chemo-radiat on the apy In 11 patients 
a baseline blood sample could not be ob ained and wer
therefore excluded from further analysi , resulting in 86 
included patients. The median OS since bas line blood 
sampling was 14 months (range 2–60). As of August 2013, 
25 out of 86 patients had not died and were thus c ored 
to this date.
Twenty-seven patients were diagnosed with recu rent 
glioma according to the RANO criteria and were scheduled 
for treatment with chemotherapy. Tumor recurrence was 
confirmed by MR imaging in 15 patients, and histological 
confirmed in 12 patients. Twenty patients were treated for 
their first recurrence and seven patients for their second. 
All patients had previously undergone urgical resection or 
stereotactic biopsy, of which six patie ts were e-operated 
once and five patients twice. Twenty patients received radio-
therapy in an earlier stage of disease and five patients were 
already treated with chemotherapy of hich one pati nt wa
treated for another malignancy (sigmoid carcinoma).
Table 1 Patient characteristics newly diagnosed glioma group
Characteristic Number of  
patients (n =  86)
Male/female ratio 59/27
Median age (y; range)a 56 (18–78)
Baseline corticosteroids yes/nob 23/63







Median total dose rth (Gy)60 (42–60)
Median number TMZ courses (n)d 6 (0–13)
Median time primary diagnosis—baseline  
S100B (days)
18 (6–56)
KPS Karnof ky Performance Score, rth radiothe apy, TMZ 
temozolomide, GBM glioblastoma, O/A oligo-astrocytoma
aAge at primary diagnosis
bCorticosteroid =  oral dexamethason
cType of surgery at primary diagnosis
dAdjuvant TMZ courses
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Discussion
In the current study we found that the majority of 
newly diagnosed and recurrent glioma patients have serum 
S100B levels within normal limits. The median serum lev-
els at baseline for the newly diagnosed and recurrent groups 
were respectively 0.049 and 0.064 µg/L. These findings are 
fairly in line with other studies, which also found median 
values within the reference range in glioma patients at dif-
ferent stages of disease [36, 42–44]. Furthermore, no sig-
nificant change over the course of treatment was found in 
both patient groups.
Although a significantly shorter survival was found for 
patients with raised levels in the recurrent glioma group, 
this was not found for the, much larger, newly diagnosed 
glioma group.
Regarding the correlation of serum S100B levels and sur-
vival in glioma patients few data are available in literature. 
Mutlu et al. found no significant association between pre-
treatment serum S100B values and OS in patients (n =  27), 
who were recently diagnosed with glioblastoma [43]. These 
results are confirmed by our findings in the newly diagnosed 
glioma group. Vos et al. found an association between serum 
levels above 0.09 µg/L and a shorter survival in glioma 
patients at different stages of treatment and disease (n =  20) 
[36]. These results are in line with the findings in our recur-
rent group. We have no clear explanation for this phenom-
enon. However, the number of patients in both the recurrent 
group in our study and the group investigated by Vos et al. 
is small and in various stages of disease, and should thus be 
interpreted with caution.
Several hypotheses concerning raised serum S100B lev-
els in glioma patients have been postulated:
(1) proliferating brain tumors can cause damage to astro-
cytes by causing a disruption of cell integrity, leading to an 
increased release of S100B, (2) disruption of the BBB also 
leads to an increase in serum S100B levels, even in absence 
of cerebral damage [19, 45, 46]. (3) craniotomy itsels may 
lead to higher S100B levels [47].
Marchi et al. published a mathematical model in which 
it is postulated that maximum serum levels achievable after 
BBB-failure are around 0.34 µg/L and thus, levels exceed-
ing these values are probably due to other factors such as 
non-CNS release or concomitant brain damage [46].
Breaching of the BBB can be assessed by the appearance 
of contrast enhancement on MRI, which is especially appar-
ent in high grade gliomas. All patients in our study showed 
contrast enhancement on MRI, indicating breaching of BBB. 
According to the model of Marchi et al. it would seem logi-
cal that the majority of patients would have elevated serum 
S100B values, however most patients showed serum levels 
within normal limits throughout various stages of disease. 
Survival analysis
In the newly diagnosed group one of the two patients dem-
onstrating the highest serum levels showed a relatively 
short survival (8 months) since baseline blood sampling. 
However, the other patient wa  still al ve as of August 
2013 with a survival of 23 months from baseline blo d 
sampling.
The patient demonstrating the highest serum level in 
the recurrent group also showed a relatively short survival 
compared to the median survival sin e baseline blood sam-
pling (6 vs. 12 months, respectively). Only one patient 
demonstrated a shorter survival of 1 month (baseline serum 
S100B: 0.107 µg/L).
When patients in both groups were dichotomized by the 
estimated upper limit of the reference range of 0.1 µg/L, no 
significant difference in survival was found in the newly 
diagnosed group.
In the recurrent group a significantly shorter survival of 
median 4 months (range 1–10) was found for patients (n =  7) 
with serum levels >0.1 µg/L compared to 16 months median 
survival (range 3–69) for patients (n =  20) with serum levels 
< 0.1 µg/L (log rank-test, p =  0.000, Fig. 2). This remained
significant after correction for age, tumor grade (dichoto-
mized according to WHO high grade vs. low grade), KPS 
at baseline and corticosteroid use at baseline with Cox pro-
portional hazard analysis (hazard ratio 4.1, 95 % confidence 
interval 1.1–15.2).
Table 2 Patient characteristics recurrent glioma group
Characteristic Number 
of patie ts 
(n = 27)
Male/female ratio 17/10
Median age (y; range)a 47 (22–66)
Baseline corticosteroids yes/nob 13/14
Median baseline KPS (range)80 (50–100)
Histology
A II–A III–O II–O III–O IVc–O/A II–O/A III–GBM3–4–2–3–1–
1–2–11
Type of chemotherapy received
TMZ 5/28/TMZ 3 weeks on, 1 week off/PCV22/4/1
Median number chemotherapy courses (n; range)6 (1–18)
Median time primary diagnosis—baseline S100B 
(mo, range)
26 (1–223)
KPS Karnofsky Performance Score, rth radiothe apy, TMZ 
temozolomide, PCV procarbazine, CCNU and vincristine, A 
astrocytoma, O oligodendroglioma, O/A oligo- strocy om , GBM 
glioblastoma
aAge at inclusion date
bCorticosteroid =  oral dexamethason
cGlioblastoma with oligodendroglial component
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recurrent glioma patients, respectively, which is signifi-
cantly longer than the interval described in literature. Fur-
thermore, we found no consistent trend in S100B levels in 
patients with resection vs. biopsy in this study.
There are several limitations to this study. First, blood 
sampling was ceased when clinical and/or radiological 
progression was apparent. As such, it was not possible to 
study the values of serum S100B after tumor progression. 
Therefore, it is recommended that serum measurements 
are continued in patients that show clinical and/or radio-
logical progression and subsequently switch to alternative 
treatments. Second, patients in the recurrent group showed 
heterogeneity regarding the stages of disease and previous 
treatment, which may have influenced survival data and/or 
Furthermore, no clear correlation (da a not s own) could 
be found between the degree of contrast enhancement and 
serum levels. In contrast, brain damag and isruption of 
the BBB caused by traumatic bra n injury and a ute stroke 
does seem to lead to raised s um S100B levels which is 
correlated to clinical outco e and mortality [22, 25, 29]. It 
remains unclear why glioma patients do not show signifi-
cant elevation of serum levels.
Syeda et al. describe temporarily (< 7 days) hig  serum 
levels of S100B in patients who underwent craniotomy for 
a brain tumor, suggesting that these values are probably 
due to surgically induced tissue damage [47]. In our s udy 
the median interval between baseli  blood sampling and 
last surgery was 18 and 247 days, in newly diagnosed and 
Fig. 1 Longitudinal dynamics 
for median serum S100B values 
during the course of therapy 
for a newly diagnosed glioma 
and b recurrent glioma. E ror
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In conclusion, the majority of glioma patients have nor-
mal serum S100B values which remains within the normal 
limits throughout the course of the disease. Serum S100B 
does not seem to have prognostic value in newly diagnosed 
glioma patients. In recurrent glioma patients S100B might 
be of value in terms of prognostication of survival.
serum S100B levels. Third, the genetic profile of our glioma 
patients was not assessed as a confounding factor in this 
study, which may have biased the results concerning the 
prognostic value of serum S100B. Last, as mentioned ear-
lier, the number of patients n the recurrent group was low 
(n = 27), which may have led to biased results.
Fig. 2 Kaplan–Meier curves 
for overall survival dichoto-
mized according to the upper 
limit of the reference range of 
0.100 µg/L for a newly diag-
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